Nyrada Announces US Patent Grant for PCSK9 Inhibitor

Confers intellectual property protection for its Cholesterol-Lowering Program

Sydney, 30 July 2021: Nyrada Inc (ASX: NYR) ("Nyrada" or "the Company") a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, is pleased to announce the grant of a new patent (number 11091466) entitled, "Heterocyclic Inhibitors of PCSK9" by the United States (US) Patent and Trademark Office, marking the first patent for the Company's Cholesterol-Lowering Program.

The composition of matter patent provides protection for Nyrada's intellectual property (IP) relating to its PCSK9 inhibitor technology in the US and forms part of the Company's active IP strategy. The patent expiry date is 16 March 2038.

Commenting on the new patent, Nyrada Chief Executive Officer, James Bonnar said: "The US is a large market where 19.4 million adults are unable to achieve a healthy cholesterol level, despite taking statin therapy. Our PCSK9 inhibitor technology is being developed as an oral treatment that can be taken as a monotherapy, or in combination with a statin as a single pill. Having patent protection in place significantly strengthens our business development position for this innovative technology.

"Encouragingly, in a recent *in vivo* efficacy study our lead cholesterol-lowering drug candidate, NYX-PCSK9i, demonstrated a 46% reduction in total cholesterol when given as a monotherapy, and a 65% reduction when dosed in combination with the leading statin drug Lipitor®. This compares favourably to the reduction achieved using Lipitor alone of 27%. Further exploratory analysis of this study will be reported as soon as the data becomes available," Mr Bonnar added.

-ENDS-

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:
Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.